<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1144">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244591</url>
  </required_header>
  <id_info>
    <org_study_id>Glucocorticoid COVID-19</org_study_id>
    <nct_id>NCT04244591</nct_id>
  </id_info>
  <brief_title>Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure</brief_title>
  <official_title>Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center, randomized, control study, the investigators will evaluate the efficacy
      and safety of glucocorticoid in combination with standard care for COVID-19 patents with
      Severe acute respiratory failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 is a novel coronavirus that was initially outbreak in Wuhan, China. Severe acute
      respiratory infection with COVID-19 causes severe acute respiratory failure with substantial
      mortality. Currently, the standard care is supportive care, and no treatment is proven to be
      effective for this condition.

      Glucocorticoid therapy is widely used among critically ill patients with other coronavirus
      infection such as SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory
      syndrome). However, whether glucocorticoid improved the outcome of COVID-19 remains unknown.
      We hypothesized that glucocorticoid would improve the prognosis of patietns with COVID-19.

      In this study, critically ill patients with COVID-19 were enrolled and randomized to receive
      ether standard care or standard care in combination with methylprednisolone therapy. The
      primary outcome is the difference of Murray lung injury score between two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2020</start_date>
  <completion_date type="Actual">April 13, 2020</completion_date>
  <primary_completion_date type="Actual">April 13, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lower Murray lung injury score</measure>
    <time_frame>7 days after randomization</time_frame>
    <description>Murray lung injury score decreased more than one point means better outcome.The Murray scoring system range from 0 to 4 according to the severity of the condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lower Murray lung injury score</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Murray lung injury score decreased more than one point means better outcome.The Murray scoring system range from 0 to 4 according to the severity of the condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference of PaO2/FiO2 between two groups</measure>
    <time_frame>7 days after randomization</time_frame>
    <description>PaO2/FiO2 denotes ratio of arterial partial pressure of O2 and the fraction of inspired oxygen, with a higher PaO2/FiO2 means favorable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>7 days after randomization</time_frame>
    <description>Lower SOFA score means better outcome. The SOFA score system range from 0 to 24 according to the severity of the condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation support</measure>
    <time_frame>7 days after randomization</time_frame>
    <description>Percentage of patients requiring Mechanical ventilation support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference of PaO2/FiO2 between two groups</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>PaO2/FiO2 denotes ratio of arterial partial pressure of O2 and the fraction of inspired oxygen, with a higher PaO2/FiO2 means favorable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lower Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Lower SOFA score means better outcome. The SOFA score system range from 0 to 24 according to the severity of the condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation support</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Percentage of patients requiring Mechanical ventilation support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of noval coronavirus</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Clearance of noval coronavirus in upper respiratory tract or lower respiratory tract</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days after randomization</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>COVID-19 Infections</condition>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care + methylprednisolone therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone 40 mg q12h for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone therapy</intervention_name>
    <description>Methylprednisolone 40 mg q12h for 5 days</description>
    <arm_group_label>standard care + methylprednisolone therapy</arm_group_label>
    <other_name>Steroids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Standard care</description>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  PCR confirmed COVID-19 infection

          -  Symptoms developed more than 7 days

          -  PaO2/FiO2 &lt; 200 mmHg

          -  Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula
             (HFNC) higher than 45 L/min for less than 48 hours

          -  Requiring ICU admission

        Exclusion Criteria:

          -  pregnancy;

          -  patients currently taking corticosteroids (cumulative 400 mg prednisone or
             equivalent);

          -  Severe underlying disease, i.e. end stage of malignancy disease or end stage of
             pulmonary disease;

          -  Severe adverse events before ICU admission, i.e. cardiac arrest;

          -  Underlying disease requiring corticosteroids;

          -  Contraindication for corticosteroids;

          -  Recruited in other clinical intervention trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical ICU,Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, Shalhoub S, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, Deeb AM, Al Mutairi H, Al-Dawood A, Merson L, Hayden FG, Fowler RA; Saudi Critical Care Trial Group. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. doi: 10.1164/rccm.201706-1172OC.</citation>
    <PMID>29161116</PMID>
  </reference>
  <reference>
    <citation>Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, Li PC, Lok KH, Ng YY, Wong WM, Yeung YM. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005 Aug;51(2):98-102.</citation>
    <PMID>16038758</PMID>
  </reference>
  <reference>
    <citation>Raghavendran K, Napolitano LM. Definition of ALI/ARDS. Crit Care Clin. 2011 Jul;27(3):429-37. doi: 10.1016/j.ccc.2011.05.006.</citation>
    <PMID>21742209</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, de Mendon√ßa A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on &quot;sepsis-related problems&quot; of the European Society of Intensive Care Medicine. Crit Care Med. 1998 Nov;26(11):1793-800.</citation>
    <PMID>9824069</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

